Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
Twenty-two patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex and multilineage hematopoietic defects were treated with recombinant granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) in a phase I/II trial. All patients were neutropenic and anemic after withdrawal of all bone marrow-suppressive drugs. Daily, G-CSF was subcutaneously self-administered until an absolute neutrophil count (ANC) greater than 6,000/microL was achieved and maintained for 2 weeks. Subcutaneous EPO was added to the regimen and the dose increased until an increase of 15 g/L of hemoglobin was observed. Groups of patients were administered increasing doses of zidovudine to determine their tolerance. G-CSF and EPO therapy was continued with dose modification to maintain an ANC greater than 1,500/microL and hemoglobin greater than 100 g/L. The dose of zidovudine was not altered. All 22 patients responded to G-CSF with a mean 10-fold increase in neutrophils occurring in less than 2 weeks. Significant increases in CD4 and CD8 cell number, lymphocyte proliferative response, and bone marrow cellularity were seen. EPO therapy increased hemoglobin in all 20 evaluable patients within 8 weeks. Sixteen patients received 1,000 mg and four patients received 1,500 mg of zidovudine per day. The reinstitution of zidovudine resulted in a decline in reticulocytes and hemoglobin and the reappearance of transfusion requirements in eight of the 20 patients, six of whom had the study medications stopped. No patient had the study medications stopped because of neutropenia or thrombocytopenia. Toxicities were mild and did not require dose modifications. Limiting dilution plasma and lymphocyte co-cultures for HIV as well as serum p24 antigen levels did not change significantly during G-CSF or combined G-CSF and EPO therapy. HIV p24 antigen decreased significantly with zidovudine therapy. Opportunistic infections occurred in 14 patients but were successfully treated with myelosuppressive antimicrobial agents, including ganciclovir, without the development of neutropenia. These results suggest that combined therapy with G-CSF and EPO may improve the neutropenia and anemia of AIDS. Combined therapy may allow the resumption of full-dose zidovudine in most patients intolerant of the hematologic effects of zidovudine without apparent alteration of HIV expression or the efficacy of zidovudine.
Miles
S A
SA
Division of Hematology-Oncology, UCLA School of Medicine.
Mitsuyasu
R T
RT
Moreno
J
J
Baldwin
G
G
Alton
N K
NK
Souza
L
L
Glaspy
J A
JA
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications / Q000628:therapy*; D001772:Blood Cell Count; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D015774:Ganciclovir / Q000627:therapeutic use; D015683:Gene Products, gag / Q000032:analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006678:HIV / Q000502:physiology; D016655:HIV Core Protein p24; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D009503:Neutropenia / Q000097:blood / Q000150:complications; D009894:Opportunistic Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D014758:Viral Core Proteins / Q000032:analysis; D014779:Virus Replication; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
D015683:Gene Products, gag; D016655:HIV Core Protein p24; D006454:Hemoglobins; D011994:Recombinant Proteins; D014758:Viral Core Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D015215:Zidovudine; D015774:Ganciclovir